georgie18
Member Level
Re: georgie18 post# 673379
Friday, February 14, 2025 9:37:47 AM
Post#
674437
of 674573
CADL...$9.00...🥳...Been a nice easy mover...
georgie18
Member Level
Re: georgie18 post# 31532
Wednesday, February 05, 2025 10:22:33 AM
Post#
31578
of 32051
CADL...$8.07...🥳...moving beautifully...
georgie18
Member Level
Re: georgie18 post# 673244
Tuesday, February 04, 2025 3:06:34 PM
Post#
673314
of 673377
CADL...$7.86...🥳
georgie18
Member Level
Re: georgie18 post# 31467
Tuesday, February 04, 2025 11:00:49 AM
Post#
31487
of 31531
CADL...$7.55...🥳...ANYBODY PAYING ATTENTION HERE...
georgie18
Member Level
Re: georgie18 post# 673062
Tuesday, February 04, 2025 9:43:19 AM
Post#
673223
of 673243
CADL...$7.38...🥳...Beauty move as price catches up to the News...
georgie18
Member Level
Re: georgie18 post# 31276
Saturday, February 01, 2025 2:12:48 PM
Post#
31345
of 31466
CADL...$7.07...🥳...Bullish Engulfing Candle Reversal signal...50/200 Crossed 100/200 ready to cross...Been loading under $7...Looking for Break/Hold of $14.85 and a run at $18 Record Highs...imo...we shall see...The price will catch up to the News...
georgie18
Member Level
Re: georgie18 post# 672206
Friday, January 31, 2025 10:28:50 AM
Post#
672943
of 673062
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...
georgie18
Member Level
Re: georgie18 post# 30885
Thursday, January 23, 2025 3:25:24 PM
Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳
georgie18
Member Level
Re: georgie18 post# 671947
Thursday, January 23, 2025 2:03:43 PM
Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...
georgie18
Member Level
Re: tw0122 post# 30782
Wednesday, January 22, 2025 4:45:28 PM
Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
Recent CADL News
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 01/21/2026 05:30:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 01:30:52 PM
- Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 • GlobeNewswire Inc. • 11/17/2025 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 01:30:54 PM
- Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 11/13/2025 01:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 01:15:27 PM
- Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors • GlobeNewswire Inc. • 11/04/2025 02:00:00 PM
- Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London • GlobeNewswire Inc. • 11/03/2025 01:05:00 PM
- Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board • GlobeNewswire Inc. • 10/16/2025 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 12:21:55 PM
- Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer • PR Newswire (US) • 10/14/2025 12:10:00 PM
- Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. • GlobeNewswire Inc. • 10/14/2025 12:10:00 PM
- Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine • GlobeNewswire Inc. • 10/14/2025 12:05:00 PM
- Candel Therapeutics to Present at the SITC 2025 Annual Meeting • GlobeNewswire Inc. • 10/03/2025 01:05:00 PM
- Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 • GlobeNewswire Inc. • 09/29/2025 12:05:00 PM
- Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 • GlobeNewswire Inc. • 09/17/2025 12:05:00 PM
- Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board • GlobeNewswire Inc. • 09/02/2025 12:05:00 PM
- Candel Therapeutics to Participate in Upcoming Investor Conferences in September • GlobeNewswire Inc. • 08/28/2025 12:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/25/2025 04:15:25 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2025 08:30:27 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/14/2025 12:39:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 12:10:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 12:07:27 PM
- Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 08/14/2025 12:05:00 PM
- Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference • GlobeNewswire Inc. • 07/30/2025 12:05:00 PM
Metavesco Congratulates DeFi Dev Corp on Becoming the Second Publicly Traded Company to Launch a Memecoin • MVCO • Jan 22, 2026 6:04 PM
Rainmaker Worldwide Strengthens North American Growth Pipeline With Affiliate Partnership Supporting Ontario's Housing Expansion • RAKR • Jan 22, 2026 10:19 AM
From Permits to Gold Pour: Why Readiness Matters • LFLR • Jan 22, 2026 9:00 AM
Cannabix Marijuana Breath Test Featured on the Cover of AlcoPro's 2026 Product Catalog • BLOZF • Jan 22, 2026 8:52 AM
Envirotech Vehicles Reaffirms Momentum With AZIO AI and Provides Update on Nasdaq Compliance Process • EVTV • Jan 21, 2026 1:25 PM
Rainmaker Worldwide Expands U.S. Operations With ATMOCELL 5K and R/OCell® Deployments in the Permian Basin • RAKR • Jan 20, 2026 11:15 AM
